Barely Significant
← all excerpts

Management of colorectal cancer.

F1000Prime Rep · 2014 · PMC4229728 · PMID 25580262

Europe PMCDOI
1
hedged sentence
0.0900
closest p · 1.8× alpha
0.0900
boldest claim

The sentences

showed a trendP = 0.09so close (0.05 < p ≤ 0.1)
A subgroup analysis of FOLFOX-treated patients showed a trend ( P = 0.09) toward longer OS in cetuximab-treated patients versus bevacizumab-treated patients, with OS 30.1 versus 26.9 months, respectively.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.